CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 8:00 a.m. ET in New York.
About Goldfinch Bio
Goldfinch Bio is a biotechnology company
that is singularly focused on discovering and developing precision
therapies for patients with kidney diseases. Just as the goldfinch has
long been a symbol of healing and renewal and was a prominent figure of
the Renaissance, Goldfinch Bio is leading a new age of therapeutic
discovery to transform the treatment paradigm for patients with kidney
diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is
headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.